HTGF sells stake in Evoxx to Advanced Enzyme

The Mumbai-based trade buyer will acquire 100% of the business. The deal is intended to strengthen its position in Germany, as well as boosting its research and development capabilities. The acquisition will also help Advanced Enzymes expand its enzyme portfolio and business in biocatalysis and food applications.

HTGF first invested in Evoxx in 2007. It has also received undisclosed levels of seed funding from Sirius Seedfonds Dusseldorf, NRW Bank and a number of angel investors.

Company
Evoxx has a team of 40 scientists and technicians across two sites in Germany – on the creative campus in Monheim am Rhein and on the biotech campus Hermannswerder in Potsdam. Its product development is based on the proprietary technology and patent platform covering the whole value chain from early enzyme and process development to industrial scale production.

People
High-Tech Gründerfonds – Kay Balster (senior investment management).
Advanced Enzymes – VL Rathi (chairperson).
Evoxx – Thorsten Eggert (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Exits
• High-Tech Gründerfonds
• Germany
• Trade sale